The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting

Biomaterials

Volumn 28, Issue 31, 2007, Pages 4673-4683

  Dandamudi, Suman ^a   Campbell, Robert B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cancer; Chemotherapy; Endothelial cell; HPLC; Magnetic liposomes; Tumor vasculature

Indexed keywords

CHEMOTHERAPY; CYTOTOXICITY; DRUG DELIVERY; DRUG PRODUCTS; LIPOSOMES; MAGNETITE; TUMORS;

MAGNETIC DRUG TARGETING; THERAPEUTIC BENEFITS; THERAPEUTICS;

ONCOLOGY;

DACARBAZINE; ETOPOSIDE; LIPOSOME; MACROGOL; MAGNETITE; VINBLASTINE SULFATE;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL VIABILITY; CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; DRUG UPTAKE; GROWTH INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DIFFUSION; DRUG DELIVERY SYSTEMS; ETOPOSIDE; FERROSOFERRIC OXIDE; MELANOMA; MICE; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34547892218     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2007.07.024     Document Type: Article

References (60)

1. Alexiou C., Schmid A., Klein R., Hulin P., Bergemann C., and Arnold W. Magnetic drug targeting: biodistribution and dependency on magnetic field strength. J Magn Magn Mater 252 (2002) 363-366
2. Zhang J.Q., Zhang Z.R., Yang H., Tan Q.Y., Qin S.R., and Qiu X.L. Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies. Pharm Res 22 4 (2005) 573-583
3. Alexiou C., Arnold W., Klein R.J., Parak F.G., Hulin P., Bergemann C., et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60 23 (2000) 6641-6648
4. Alexiou C., Jurgons R., Schmid R.J., Bergemann C., Henke J., Erhardt W., et al. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11 3 (2003) 139-149
5. Widder K.J., Senyei A.E., and Ranney D.F. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv Pharmacol Chemother 16 (1979) 213-271
6. Lubbe A.S., Bergemann C., Brock J., and McClure D.G. Physiological aspects in magnetic drug-targeting. J Magn Magn Mater 194 (1999) 149-155
7. Hirao K., Sugita T., Kubo T., Igarashi K., Tanimoto K., Murakami T., et al. Targeted gene delivery to human osteocarcinoma cells with magnetic cationic liposomes under a magnetic field. Int J Oncol 22 (2003) 1065-1071
8. Hassan E.E., and Gallo J.M. Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microsperes. J Drug Target 1 (1993) 7-14
9. Kubo T., Sugita T., Shimose S., Nitta Y., Ikuta Y., and Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol 18 1 (2001) 121-125
10. Nobuto H., Sugita T., Kubo T., Shimose S., Yasunaga Y., Murakami T., et al. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer 109 4 (2004) 627-635
11. Fortin-Ripoche J.P., Martina M.S., Gazeau F., Menager C., Wilhelm C., Bacri J.C., et al. Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. Radiology 239 2 (2006) 415-424
12. Suzuki M., Shinkai M., Honda H., and Kobayashi T. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 13 2 (2003) 129-135
13. Ito A., Ino K., Kobayashi T., and Honda H. The effect of RGD peptide-conjugated magnetite cationic liposomes on cell growth and cell sheet harvesting. Biomaterials 26 31 (2005) 6185-6193
14. Folkman J. The role of angiogenesis in tumor growth. Sem Cancer Biol 3 (1992) 65-71
15. Shubik P. Vascularization of tumors; a review. J Cancer Res Clin Oncol 103 (1982) 211-226
16. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10 (2004) 415-427
17. Kunstfeld R., Wickenhauser G., Michaelis U., Teifel M., Umek W., Naujoks K., et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 120 3 (2003) 476-482
18. Strieth S., Eichhorn M.E., Sauer B., Schulze B., Teifel M., Michaelis U., et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 110 1 (2004) 117-124
19. Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101 7 (1998) 1401-1413
20. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62 23 (2002) 6831-6836
21. Lev D.C., Onn A., Melinkova V.O., Miller C., Stone V., Ruiz M., et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 22 11 (2004) 2092-2100
22. Chapman P.B., Einhorn L.H., Meyers M.L., Saxman S., Destro A.N., Panageas K.S., et al. Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 9 (1999) 2745-2751
23. Owellen R.J., Hartke C.A., Dickerson R.M., and Hains F.O. Inhibition of tubulin-microtubule polymerization by drugs of the vinka alkaloid class. Cancer Res 36 (1976) 1499-1502
24. Owellen R.J., Owens A.H., and Donigian D.W. The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 47 (1972) 685-691
25. Lobert S., Vulevic B., and Correia J.J. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 35 (1996) 6806-6814
26. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34 (1998) 1514-1521
27. Burden D.A., Kingma P.S., Froelich-Ammon S.J., Bjornstii M.A., Patchan M.W., Thompson R.B., et al. Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem 271 (1996) 29238-29244
28. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88 24 (1991) 11460-11464
29. Dandamudi S., and Campbell R.B. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim Biophys Acta 1768 3 (2007) 427-438
30. Campbell R.B., Balasubramanian S.V., and Straubinger R.M. Phospholipid-cationic lipid interactions: influences on membrane and vesicle properties. Biochim Biophys Acta 1512 1 (2001) 27-39
31. Owen C.S., and Sykes N.L. Magnetic labeling and cell sorting. J Immunol Methods 73 1 (1984) 41-48
32. Kato Y., Mawatari H., Nishimura S., Sakura N., and Ueda K. Determination of etoposide serum concentration in small pediatric samples by an improved method of reversed-phase high-performance liquid chromatography. Acta Med Okayama 57 1 (2003) 21-24
33. Maswadeh H., Demetzos C., Dimas K., Loukas Y.L., Georgopoulos A., Mavromaoustakos T., et al. In-vitro cytotoxic/cytostatic activity of anionic liposomes containing vinblastine against leukaemic human cell lines. J Pharm Pharmacol 54 (2002) 189-196
34. Safgren S.L., Reid J.M., Rios R., and Ames M.M. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. J Chromatogr B Biomed Sci Appl 754 1 (2001) 91-96
35. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 13 (1990) 1107-1112
36. Kalra A.V., and Campbell R.B. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: implications for tumor vascular targeting. Pharm Res 23 12 (2006) 2809-2817
37. Ricotti L., Tesei A., De Paola F., Ulivi P., Frassineti G.L., Milandri C., et al. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 9 2 (2003) 900-905
38. Jain R.K., Munn L.L., and Fukumara D. Dissecting tumor pathophysiology using intravital microscopy. Nat Rev Cancer 2 (2002) 266-276
39. Babincova M., Altanerova V., Lampert M., Altaner C., Machova E., Sramka M., et al. Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field. Z Naturforsch [C] 55 3-4 (2000) 278-281
40. Cohen G.L., and Falkson C.I. Current treatment options for malignant melanoma. Drugs 55 6 (1998) 791-799
41. McLean J.W., Fox E.A., Baluk P., Bolton P.B., Haskell A., Pearlman R., et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol 273 1, Part 2 (1997) H387-H404
42. Babincova M., Altanerova V., Altaner C., Cicmanec P., and Babinec P. In vivo heating of magnetic nanoparticles in alternating magnetic field. Med Phys 31 8 (2004) 2219-2221
43. Babincova M., Sourivong P., Chorvat D., and Babinec P. Laser triggered drug release from magnetoliposomes. J Magn Magn Mater 194 (1999) 163-166
44. Babincova M., Cicmanec P., Altanerova V., Altaner C., and Babinec P. AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy. Bioelectrochemistry 55 1-2 (2002) 17-19
45. Viglianti B.L., Abraham S.A., Michelich C.R., Yarmolenko P.S., MacFall J.R., Bally M.B., et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 51 6 (2004) 1153-1162
46. Okuhata Y. Delivery of diagnostic agents for magnetic resonance imaging. Adv Drug Deliv Rev 37 1-3 (1999) 121-137
47. Bulte J.W., and De Cuyper M. Magnetoliposomes as contrast agents. Methods Enzymol 373 (2003) 175-198
48. Babincova M., Leszczynska D., Sourivong P., Babinec P., and Leszczynski J. Principles of magnetodynamic chemotherapy. Med Hypotheses 62 3 (2004) 375-377
49. Wu J., Lee A., Lu Y., and Lee R.J. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 337 1-2 (2007) 329-335
50. Sengupta S., Tyagi P., Velpandian T., Gupta Y.K., and Gupta S.K. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res 42 5 (2000) 459-464
51. Campbell R.B., Balasubramanian S.V., and Straubinger R.M. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J Pharm Sci 90 8 (2001) 1091-1105
52. Pitot H.C. Cancer-an overview. In: Lafond E.R. (Ed). Cancer: the outlaw cell. 2nd ed (1988), American Chemical Society, Washington 1-18
53. Atallah E., and Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6 3 (2005) 185-193
54. Lewis K.D., Robinson W.A., McCarter M., Pearlman N., O'Day S.J., Anderson C., et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 24 19 (2006) 3157-3163
55. Lee C.M., Choi Y., Huh E.J., Lee K.Y., Song H.C., Sun M.J., et al. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. Cancer Biother Radiopharm 20 6 (2005) 620-628
56. Garbuzenko O., Barenholz Y., and Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 135 2 (2005) 117-129
57. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 104 3 (2007) 932-936
58. Weinberg E.D. The role of iron in cancer. Eur J Cancer Prev 5 1 (1996) 19-36
59. Simonart T., Noel J.C., Andrei G., Parent D., Van Vooren J.P., Hermans P., et al. Iron as a potential co-factor in the pathogenesis of Kaposi's sarcoma?. Int J Cancer 78 6 (1998) 720-726
60. Drevs J., Fakler J., Eisele S., Medinger M., Bing G., Esser N., et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24 3a (2004) 1759-1763